Abstract. Exposure to a low dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) results in a variety of toxic manifestations, including fetal death. In order to evaluate the effects of low dose TCDD on placental function, pregnant Holtzman rats were given a single oral dose of 1600 ng TCDD/kg body wt or an equivalent volume of vehicle (control) on gestation day 15 (GD15), and changes in the gene expression in the placenta on GD20 were analyzed by two comprehensive methods, representational difference analysis (RDA) and DNA microarray technology. Candidates of TCDD-inducible and -suppressive genes were selected. Quantitative real-time PCR analysis was then performed to verify the induction or suppression levels of the candidate genes. Finally, we identified 81 TCDD-inducible and 21 TCDD-suppressive genes from the placenta of TCDD-treated Holtzman rats on GD20. One of the remarkable profiles of the gene expression was that glucose transporters were strongly up-regulated by the TCDD treatment. Furthermore, many interferon-inducible genes were also up-regulated by the treatment. They included several cytokines such as IP-10 known as a potent angiogenesis inhibitor. In addition, interferon molecules are known to suppress angiogenesis. The above observations suggest that activation of the interferon signaling pathway and the induction of anti-angiogenic factors by TCDD might have a role in causing the inhibition of neovascularization, resulting in the hypoxic state of placenta and increased incidence of fetal death.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is known to be the most toxic congener among the dioxin and related compounds found in the environment. Exposure to TCDD causes a diverse spectrum of toxicities in humans and laboratory animals [1] [2] [3] [4] . The fetus is one of the most sensitive targets of TCDD and exhibits a wide range of biological responses at low TCDD levels that have no detectable effects on maternal side (usually the levels were ten to hundred times lower than those of LD50). One of the most severe adverse effects of TCDD is intrauterine fetal death [1, [5] [6] [7] . The incidence has been shown in all species studied to date, including the monkey, hamster, rat, and mouse. Although fetal death is an important aspect of TCDD toxicity, its precise mechanism is not well understood. Placenta plays a crucial role in maintaining normal fetal growth such as exchange of oxygen and carbohydrate nutrients. In previous studies Ishimura et al. demonstrated that exposure of pregnant rats to 800 or 1600 ng TCDD/kg on gestational day 15 (GD15) resulted in an increased incidence of fetal death on GD20 [8, 9] . In their experimental protocol, the placenta showed several abnormalities that led to increased risk for fetal death. Exposure to TCDD altered the glucose kinetics in placenta [8] and caused reduced blood flow and placental hypoxia [9] , leading them to hypothesize that the increased incidence of the fetal death may be due to reduced blood flow into the placenta [8, 9] . In order to clarify what kind of genes are involved in these placental abnormalities or what other aspects of TCDD toxicities exist in the placenta, we conducted a comprehensive analysis of gene expression in placenta of pregnant Holtzman rats treated with TCDD using representational difference analysis (RDA) and DNA microarray technology. RDA is a subtraction cloning method developed by Pastorian et al. [10] . The RDA and the DNA microarray are very powerful and comprehensive methods to identify inducible or suppressive genes by given hormonal or pharmacological treatments. Previously we have reported many gonadotropin-inducible genes in the rat ovary by using those methods [11] [12] [13] . In this study, many candidates for placental TCDD-inducible or -suppressive genes were selected by those methods, and the induction or suppression was verified by quantitative real-time PCR.
Profiling analysis of the verified genes revealed that, in addition to the genes involved in the glucose uptake, those involved in the interferon signaling pathway were strongly induced by the TCDD treatment. Based on the results obtained, the molecular mechanisms of placental disorders by low dose TCDD will be discussed.
Materials and Methods
Reagents 2,3,7,8-TCDD was obtained from Cambridge Isotope Laboratory (Andover, MA). Rat cDNA glass array (Gene Chip Rat Expression Array 230A) was from Affymetrix, Inc., Santa Clara, CA.
Animals
Holtzman rats were purchased from Harlan SpragueDawley (Indianapolis, IN). The animals were maintained in a controlled environment with 12/12 h light/ dark cycles, and given free access to laboratory rat chow and water. Female rats were allowed to mate on proestrus overnight, and, if vaginal plugs were observed in the morning, the day was designated GD0. Six pregnant rats were treated with TCDD, and a total of 10 dead fetuses was observed among 83 fetuses. The pregnant rats were housed individually until exercised. All animal experiments were performed according to the guidelines for animal welfare of the National Institute for Environmental Studies [8, 9] .
TCDD treatment
The pregnant animals were exposed to TCDD as described previously [8, 9] . TCDD was dissolved in nonane at a concentration of 20 mg/ml, and the solution was diluted with corn oil. On GD15 the pregnant rats were given a single oral dose of 1600 ng TCDD/kg body wt or an equivalent volume of mixture of nonane and corn oil solution (control). Placentas were collected from the TCDD treated or control rats on GD20. The placental samples were immediately frozen in liquid nitrogen and maintained at -80°C until used.
Representational difference analysis
For isolating TCDD-inducible and -suppressive genes from the placenta, representational difference analysis (RDA) was performed according to the procedure reported by Pastorian et al. [10] . Briefly, total RNA was extracted from each placenta. Each five placental RNA samples were mixed and used for further analysis. After Oligo-dT latex beads treatment, mRNA preparations were then converted to respective double-stranded cDNAs. Tester TCDD-treated placental cDNAs and driver control placental cDNAs were digested with a restriction enzyme DpnII. The digested tester cDNA fragments were ligated with first-round adaptor oligonucleotide molecules, and then mixed with the excess amount of the enzyme digested driver cDNAs. The mixture was denatured and then incubated at 67°C for 16 hours for hybridization. After the hybridization, only the tester specific cDNA fragments were amplified by PCR reaction using primers complementary to the adaptor sequence. For the second cycle RDA, the resulting PCR products, in which the tester specific cDNA fragments were enriched, were digested again with DpnII, and then followed by the second adaptor ligation and hybridization in order to further enrich tester specific cDNA fragments. The PCR products after the second RDA reaction were ligated in to pGEM T-vector, and individual clones were analyzed to identify TCDD-sensitive genes.
DNA microarray
The microarray method was carried out according to the manufacturer's instruction.
Briefly, total RNA was extracted from the TCDDtreated and control placentas described above. Double stranded cDNA libraries were constructed from the mRNA of TCDD-treated and the control placentas using an oligo-dT primer with a T7-promoter sequence at the 5'-end. Biotin-labeled complementary RNA was in vitro transcribed by T7 polymerase using the cDNA libraries as template. The biotin-labeled RNA was fragmented and hybridized to the Rat cDNA glass array for 16 hr at 45°C and then washed and stained using the GeneChip Fluidics. The array was scanned by a GeneArray scanner, and hybridization patterns were detected as fluorescent light from reporter groups that have been incorporated into the target genes. The average difference measurements computed in the Affymetrix Microarray Analysis Suite 4.0 serve as a relative indicator of the level of expression.
Quantitative Real-Time PCR Messenger RNA was extracted using an RNA extraction solution (Trizol) and oligo-dT latex beads as described previously [11] [12] [13] . Five micrograms of mRNA preparations were reverse-transcribed, and then converted to double stranded cDNA molecules. Complementary DNA was quantified by UV absorption measurement, and 1 ng was subjected to the PCR reaction as template. As an internal standard, TATA binding protein (TBP) was used instead of GAPDH, since GAPDH gene expression was affected by the TCDD treatment (data not shown). PCR reaction involved template cDNA samples, Advantage Taq Plus DNA polymerase (Clontech), dNTP, and Syber Green. Serial dilutions of the templates were used to create a concentration curve, and relative expression levels were calculated for each sample [14] . Abundance of each gene was referred to as a Ct (cycle threshold) value in this system.
Results
Exposure of pregnant Holtzman rats to 1600 ng TCDD/kg on GD15 resulted in an increased incidence of fetal death on GD20 [8, 9] . In these studies, each placenta from the TCDD-treated and control rats was prepared by the same exposure protocol as previous studies [8, 9] , and gene expression in the placenta was analyzed by RDA and DNA microarray methods. Generally the RDA method is more sensitive than the DNA microarray, while the latter covers more comprehensive genes than the RDA method. A total of 2536 clones were picked-up and characterized from the RDA-subtracted cDNA libraries as candidate genes. In addition, the same tissues were used for the DNAmicroarray, and among 13000 genes spotted on the array, 43 TCDD-inducible and 18 TCDD-suppressive candidate genes (cut-off values of 2.0 as inducible and 0.5 as suppressive genes) were also picked-up. All of these candidate genes picked-up by both methods were verified by using real-time PCR analysis, and genes that showed expression ratios (TCDD-treated/control) of more than 2.0 or less than 0.5 were finally identified as TCDD-sensitive. TCDD-inducible and -suppressive genes in the rat placenta identified by RDA and DNA microarray methods were summarized in Table 1 and  Table 2 , respectively.
TCDD-inducible genes in the placenta
As listed in Table 1 , 81 genes were identified as TCDD-inducible genes in the placenta, 22 genes of which were from the results of DNA microarray analysis. Eleven genes were reported only on EST databases, and one gene showed no significant similarity to any gene on DNA databases. Other genes were all annotated as shown in Table 1 including those homologues of human or mouse. They were categorized into several groups. Enzyme genes include CYP1A1 and CYP1B1 that are known as the typical TCDD target genes [15, 16] . Inducible genes in placenta include some of the major blood proteins, such as prealbumin, apolipoproteins, transferrin, retinol-binding protein, prothrombin, and fibrinogens. This suggests that the placental production of the blood proteins was stimulated by the TCDD treatment. In addition, two placental specific genes, alpha-fetoprotein and pregnancy-specific glycoprotein (rnCGM3), were also induced by the TCDD treatment. Two characteristic profiles of the induction were (1) glucose transporters and (2) interferon-related genes, details of which will be described elsewhere.
TCDD-suppressive genes in the placenta
As listed in Table 2 , 21 genes were identified as TCDD-suppressive genes in the placenta, 10 genes of which were from the results of the DNA microarray analysis. Six genes were reported only on EST databases, and three genes showed no significant similarity to any gene on existing DNA databases. Other genes were all annotated as shown in Table 2 including those homologues of human or mouse.
Induction of glucose transporter family genes
As shown in Fig. 1 , expressions of four major glucose transporter genes were examined. Quantitative real-time PCR revealed that GLUT2 and GLUT4 were strongly induced by the TCDD treatment in the placenta. Gene expression of GLUT3 was also marginally increased by the treatment (1.58-fold), but that of GLUT1 was less affected (1.24-fold). In the control placenta, GLUT3 was abundantly expressed (Ct26.57), while expression levels of the other three transporter genes were relatively low (Ct32.73 for GLUT1, Ct31.47 for GLUT2, and Ct31.49 for GLUT4). Therefore, in addition to the remarkable induction of GLUT2 and GLUT4 genes, a small but significant increase in GLUT3 gene expression may have a major physiolog- ical significance of the glucose-uptake in the TCDDtreated placenta.
Induction of interferon-related genes
One of the most remarkable findings of the pesent experiment was that many interferon-regulated genes were induced in the placenta of TCDD-treated animals. As shown in Fig. 2, 15 out of 18 interferon-inducible genes examined were strongly up-regulated by the TCDD treatment. Among them were interferoninducible cytokines, such as IP-10 [17, 18] , macrophage inflammatory protein-2, monokine induced by gamma interferon (Mig) [19] and CXC chemokine LIX [20] . Of these, IP-10 was reported to be involved in the interferon-mediated inhibition of angiogenesis [17, 18] . Since many interferon-inducible genes were up-regulated by the TCDD-treatment, we examined the levels of interferon family genes. At the transcription levels, the interferon beta gene was up-regulated (5.07-fold induction) in the TCDD-treated placenta (Table. 1), but we were not able to detect interferonalpha and -gamma genes in our system (data not shown). Expression levels of major 4 glucose transporter genes were determined by quantitative real-time PCR, and changes in the expression levels were compared. Values were expressed as fold induction (TCDD/control). Serial dilutions of five points for each sample were used to make each dilution curve. TATA binding protein (TBP) was used as an internal standard to ensure equal loading of template cDNA molecules.
Discussion
Previous studies have shown that a very low dose of TCDD results in the increased incidence of fetal death [8, 9] . Histological and protein profiling analysis revealed that the fetal death after the TCDD treatment may be due to the placental hypoxia [9] . In order to evaluate further the mechanisms of the induction of such the adverse effect, comprehensive analysis was done to examine changes in the placental gene expression. As clearly shown in Fig. 1 , glucose transporter genes were all induced after the TCDD treatment. Ishimura et al. previously reported the histopathological changes in glycogen cells and the elevated levels of glucose content and GLUT3 mRNA expression in the placenta of the TCDD-exposed rats in comparison to those of the control rats [9] . In addition to GLUT3 mRNA, we showed here that GLUT2 and GLUT4 mRNAs were strongly induced by the TCDD-treatment, and that GLUT1 mRNA was less affected by the treatment, indicating that most of major glucose transporter genes were up-regulated by TCDD, which may lead to glycogen accumulation in the placenta. In our quantitative real-time PCR system, values of cycle threshold (Ct) represent expression levels of genes. The Ct value of GLUT3 mRNA was much lower than those of other GLUT family genes, suggesting that the major glucose transporter working in the placenta may be GLUT3, though strong induction of GLUT2 and GLUT4 genes may also play significant roles in the glucose accumulation in the TCDD-treated placenta. As far as we know, this is the first report describing that GLUT2 and GLUT4 genes were actually expressed in the placenta under specific conditions such as the TCDD treatment. It is likely that a tissue-specific responsive mechanism of TCDD exists for the induction of glucose transporters in the placenta, since those transporter genes were not up-regulated in other tissues such as the ovary from the same TCDD-treated animals (data not shown). Histological studies by Ishimura et al. showed that blood vessel formation in the placenta was severely impaired by the TCDD treatment (unpublished data), indicating that the angiogenesis was inhibited in the placentas of TCDD-treated animals on GD20. Therefore, the TCDD treatment may cause hypoxic conditions in placenta. It was reported that the expression of GLUT-1 and GLUT-3 mRNAs was up-regulated under hypoxic conditions [21] .
Most striking observation of this experiment was that many interferon-inducible genes were up-regulated in the placenta of TCDD-treated animals. As shown in Fig. 2, 15 out of 18 interferon-inducible genes examined were induced by the TCDD treatment, which strongly suggests that interferon signaling pathway Expression levels of 18 interferon regulated genes were determined by quantitative real-time PCR, and changes in the expression levels were compared. Values were expressed as fold induction (TCDD/control). Serial dilutions of five points for each sample were used to make each dilution curve. TATA binding protein (TBP) was used as an internal standard to ensure equal loading of template cDNA molecules.
[22] was activated by the TCDD treatment. We also examined the expression levels of interferon-alpha, -beta, and -gamma by the real-time PCR analysis. Only interferon-beta gene expression was detected, and the level was strongly up-regulated by the TCDD treatment. Although the data suggest that interferon-beta is the key factor, we must take into consideration of the fact that the interferon signaling pathway is activated by many other signaling molecules [23] . The typical interferon signaling pathway is activated through the JAK-STAT system [22] . It is well known that pituitary hormone GH and prolactin also activate the JAK-STAT system [23] , and that several prolactin-like molecules including placental lactogen are abundantly produced in the placenta [24] . We can not exclude the possibility that, in addition to interferon-beta, the prolactin-like molecules produced in the placenta may also play significant roles in the induction of interferonregulated genes. It is noteworthy that interferon is known to be involved in the regulation of angiogenesis. Interferonalpha and -gamma were reported to inhibit endothelial cell proliferation [25] . IP-10, one of the interferoninducible genes, was also strongly induced in the TCDD-treated rat placenta. IP-10 is a member of the alpha-chemokine family, inhibits bone marrow colony formation, has anti-tumor activity in vivo, is chemoattractant for monocytes and T cells, and promotes T cell adhesion to endothelial cells. In addition to the above functions, IP-10 has been reported to be a potent inhibitor of angiogenesis in vivo [17, 18] . Furthermore, thrombospondin [26] and tissue inhibitor of metalloproteinase 1 (TIMP-1) [27] were also induced by the TCDD treatment, both of which are known to inhibit endothelial cell proliferation. Considering the above observations, the neovascularization in the placenta on GD20 may be impaired by the TCDD treatment through the induction of anti-angiogenic factors.
It is reasonable to speculate that the hypoxic state in the placentas of TCDD-treated rats may be due to the impairment of angiogenesis in the placenta, which may be caused by the activation of the interferon signaling pathway including the production of angiogenesisinhibitory cytokine IP-10 as well as the production of anti-angiogenic factors such as thrombospondin and TIMP-1.
In conclusion, we identified 81 dioxin-inducible genes and 21 dioxin-suppressive genes from the placenta of TCDD-treated Holtzman rats on GD20. The present study revealed that glucose transporters were strongly up-regulated by the TCDD treatment.
In addition, many interferon-inducible genes were also up-regulated by the TCDD treatment, including IP-10, a potent angiogenesis-inhibitory cytokine. Activation of the interferon signaling pathway and the induction of anti-angiogenic factors may result in the hypoxic state of placenta, which may lead to the increased incidence of fetal death.
